An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

Abstract

Methods of economic evaluation, especially cost-effectiveness analysis and cost–benefit analysis, are widely used to examine new healthcare technologies. However, few economic evaluations of pharmacogenomics have been conducted, and pharmacogenomic researchers may be unfamiliar with how to review or conduct these analyses. This review provides an overview of the methods of economic evaluation and examples of where they have been applied to pharmacogenomics. We discuss the steps in conducting a cost-effectiveness or cost–benefit analysis, demonstrating these steps using specific examples from the pharmacogenomics literature.